Rallybio shareholders elect three Class II directors and ratify auditor at 2023 annual meeting

Rallybio Corp

Helen Boudreau, Lucian Iancovici, and Christine Nash elected as Class II directors for terms expiring 2025.
Vote totals: Boudreau 18,762,070 for, 6,047,659 against; Iancovici 18,875,144 for, 5,934,499 against; Nash 18,763,528 for, 6,046,201 against.
Appointment of Deloitte & Touche as independent auditor for FY2023 ratified with 27,911,030 for, 4,866 against, 230 abstain.

item 5.07

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Rallybio Corp shareholders approved Election of Class II directors at the 2023-05-17 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-05-17

Exact text from the filing

The following nominees were elected to the Board of Directors as Class II directors for terms expiring at the 2025 annual meeting of shareholders. For Against Abstentions/Broker Non-Votes Helen Boudreau 18,762,070 6,047,659 3,106,397 Lucian Iancovici 18,875,144 5,934,499 3,106,483 Christine Nash 18,763,528 6,046,201 3,106,397

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Rallybio Corp shareholders approved Ratification of appointment of Deloitte and Touche LLP as independent auditor at the 2023-05-17 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-05-17

Exact text from the filing

The shareholders ratified the appointment of Deloitte and Touche LLP as the independent registered public accounting firm for Rallybio for the fiscal year ending December 31, 2023. For Against Abstain 27,911,030 4,866 230

View on SEC.gov

Browse all shareholder votes →

Rallybio Corp filing history →

Source: SEC EDGAR

accession 0000950170-23-023468

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.